AC
IRWD icon

Apex Capital’s Ironwood Pharmaceuticals IRWD Stock Holding History

Apex Capital’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-537,300
Closed -$5.54M – 73
2014
Q1 		$5.54M Buy
+537,300
New +$6.04M 0.39% 55

Other funds holding IRWD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Apex Capital's IRWD Position: Q2 2014 in Review

Apex Capital sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2014, closing a stake of 537,300 shares — an estimated $5.54M sold.

Apex Capital first reported a position in IRWD in Q1 2014 and held it in 1 quarter. The position peaked at $5.54M in Q1 2014. 138 funds tracked by Wall St. Rank hold IRWD as of Q2 2014.

  • Apex Capital reported no remaining Ironwood Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Apex Capital sold 537,300 Ironwood Pharmaceuticals shares in Q2 2014, an estimated $5.54M.
  • Apex Capital first reported a position in Ironwood Pharmaceuticals in Q1 2014 and held it in 1 quarter.
  • Apex Capital's Ironwood Pharmaceuticals position peaked at $5.54M in Q1 2014.
  • 138 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2014.

Based on Apex Capital's 13F filing for Q2 2014, filed 7 Aug 2014.